News tagged with capecitabine
Related topics: breast cancer
Capecitabine
Capecitabine (INN) ( /keɪpˈsaɪtəbiːn/) (Xeloda, Roche) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.[citation needed] The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil.[citation needed]
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Drug combination shrinks secondary brain tumours in breast cancer without substantial side effects of radiotherapy
The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological ...
Cancer
Nov 01, 2012 |
5 / 5 (1) |
0
Diltiazem relieves capecitabine-induced chest pain
(HealthDay)—Secondary prophylaxis with diltiazem may offer cancer patients relief from capecitabine-induced chest pain and dyspnea and allow them to tolerate capecitabine treatment, according to a study ...
Cardiology
Nov 16, 2012 |
5 / 5 (1) |
0
Biomarker analysis identified women most likely to benefit from T-DM1
For women with metastatic, HER2-positive breast cancer, the amount of HER2 on their tumor might determine how much they benefit from a drug called trastuzumab emtansine (T-DM1), according to data from a subanalysis of the ...
Cancer
Apr 07, 2013 |
not rated yet |
0
Phase I study of temsirolimus, capecitabine proves safe; positive survival trend seen
A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients. In addition, the Georgetown Lombardi Comprehensive ...
Cancer
May 16, 2012 |
5 / 5 (1) |
0
Added benefit of eribulin in breast cancer is not proven
Eribulin (trade name: Halaven) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.
Cancer
Aug 16, 2012 |
not rated yet |
0
Chemo plus radiation before surgery increases tumor response for rectal cancer
Rectal cancer patients who use a new combination of the chemotherapy, Capecitabine, together with five weeks of radiation (50 Gy) before surgery have an 88 percent chance of surviving the cancer three years after treatment, ...
Cancer
Sep 26, 2011 |
not rated yet |
0
Adding erlotinib to bevacizumab/chemoradiotherapy regimen for pancreatic cancer safe, tolerable
The addition of high doses of erlotinib to the treatment regimen of bevacizumab and capecitabine with radiotherapy seems to benefit patients with locally advanced pancreatic cancer, according to results of a phase I study ...
Cancer
Jun 19, 2012 |
not rated yet |
0
Study compares standard against newer treatment in women whose breast cancer has spread
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, ...
Cancer
Dec 07, 2012 |
not rated yet |
0
New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, ...
Cancer
Dec 08, 2012 |
not rated yet |
0
